Fibronostics

Thank You for an Amazing AASLD 2024! The 75th Annual Liver Meeting in San Diego has been a fantastic experience, and we at Fibronostics want to express our heartfelt gratitude to everyone who stopped by Booth 1724 to connect with us. From engaging discussions about LIVERFASt? and our latest research to building new collaborations and strengthening existing partnerships, it was a pleasure meeting so many passionate professionals dedicated to advancing liver health. Let’s keep the conversation going! If we didn’t get a chance to connect or you’d like to continue discussing how we can work together, feel free to reach out—we’d love to hear from you. Thank you again for making this event memorable. Together, we can make a real difference in liver health care! #AASLD2024 #ThankYou #Fibronostics #LIVERFASt #Fibroconference

Today, on International Men's Day, we celebrate the contributions and achievements of men around the world. It’s also an important moment to reflect on the challenges men face, especially when it comes to their health - especially liver health. Men are at higher risk for liver conditions like fatty liver disease and cirrhosis, often due to factors like poor diet, alcohol consumption, and sedentary lifestyles. The good news? These risks are preventable with early detection and simple lifestyle changes. Encourage the men in your life to:? 1?? Get regular health check-ups 2?? Stay active and eat healthier 3?? Learn about liver health risks Let’s break the stigma and help men lead healthier lives. #InternationalMensDay #MensHealth #LiverHealth #LIVERFASt #LIVERSTAT

Don’t Miss Us at AASLD 2024! The Fibronostics team is live at the 75th Annual AASLD Liver Meeting? in San Diego, CA! Catch us at Booth 1724 to explore LIVERFASt?, our non-invasive solution for liver health assessment, and hear about our exciting poster presentation on its high performance in diagnosing fibrosis in MASLD patients. This is your chance to meet our team & experts, including our President Sven Henrichwark, CEO Brock Smith, Chief Medical Officer Dr. Ronald Quiambao, MD, and Chief Scientific Officer Dr. Mona Munteanu. Let’s discuss liver health innovations, and learn how LIVERFASt? is transforming care for patients worldwide. We’re here through November 19th—come say hello and let’s connect! #AASLD2024 #LiverMeeting #Fibronostics #LIVERFASt #Fibroconference?#MeetOurTeam

This upcoming AASLD Liver Meeting? 2024, Fibronostics will be presenting a poster that highlights findings on our LIVERFASt? Fibrosis test. The study aimed to assess the diagnostic performance of LIVERFASt? against liver biopsy results using a dataset from MASLD patients. Here’s what we discovered: ? The LIVERFASt? Fibrosis test demonstrates high performance in identifying MASLD patients with cirrhosis or MASH-related fibrosis. ? It’s equally effective in MASLD patients with or without Type 2 Diabetes (T2DM).? ? According to LIVERFASt?, MASLD patients with three or more metabolic syndrome factors or T2DM showed more severe liver fibrosis than those with fewer MetS factors or without diabetes. These findings underscore the potential of LIVERFASt? to provide a non-invasive, effective approach to diagnosing and monitoring liver fibrosis in MASLD patients. If you’re attending The Liver Meeting? 2024 in San Diego, we invite you to visit us at Booth 1724 and check out our poster presentation. Let’s discuss how LIVERFASt? can transform liver health management. #AASLD2024 #LiverMeeting #Fibronostics #LIVERFASt #Fibroconference #MeetOurTeam #LiverHealth

The wait is almost over! Just ONE DAY to go until The Liver Meeting? 2024 begins in San Diego! We can’t wait to connect with you at the 75th Annual AASLD Liver Meeting! Stop by Booth 1724 to meet our team, explore LIVERFASt?, and learn more about our latest research in liver health, including our poster presentation on the diagnostic performance of LIVERFASt? in MASLD patients. Don’t miss this opportunity to engage with us and discover how Fibronostics is advancing liver care through cutting-edge innovation. See you tomorrow in San Diego! #AASLD2024 #LiverMeeting #Fibronostics #LIVERFASt #Fibroconference #MeetOurTeam

The countdown is on! Just days to go until The Liver Meeting? 2024 in San Diego, CA! We’re thrilled to be part of the 75th Annual AASLD Liver Meeting from November 15-19, where we'll be showcasing LIVERFASt? and presenting our latest research in liver health. Come by Booth 1724 to meet our team, including our President Sven Henrichwark, CEO Brock Smith, Chief Medical Officer Ronald Quiambao, MD, and Chief Scientific Officer Mona Munteanu. Don’t miss this chance to connect and learn how Fibronostics is advancing liver care through innovation. See you there! #AASLD2024 #LiverMeeting #LiverHealth #Fibroconference?#MeetOurTeam?#LIVERFASt

Exciting news! We’re just under two weeks away from The AASLD Liver Meeting 2024! Join Fibronostics at the 75th Annual AASLD Liver Meeting from November 15-19 in beautiful San Diego, CA, where we’ll be presenting a poster on the latest in liver health advancements. It’s a great opportunity to connect, share insights, and see how our solutions are paving the way for more accessible and efficient liver health management. Don’t miss the chance to meet our dedicated team, who’ll be ready to discuss our innovative tools and answer any questions you may have. Let’s shape the future of liver health together! #AASLD2024 #LiverMeeting #Fibronostics #LIVERFASt #Fibroconference #MeetOurTeam

November is Diabetes Awareness Month – an important time to shine a light on the connections between diabetes and liver health! Diabetes is often linked to complications we may immediately think of, like heart disease and neuropathy, but there's another critical connection that's sometimes overlooked: liver health. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the world’s population and is particularly common among people with type 2 diabetes. When left unchecked, it can progress to more serious liver conditions, like nonalcoholic steatohepatitis (NASH), cirrhosis, and even liver cancer. Why is this important? The liver plays a key role in regulating blood sugar, managing cholesterol, and filtering toxins. When it’s not functioning optimally, managing diabetes becomes much more complex. Routine liver health assessments should be an essential part of diabetes care. During this month, let’s elevate the conversation around proactive liver health management, encourage regular liver screenings, and foster a more integrated approach to treating diabetes and related conditions. It’s time we bridge these health insights to promote better long-term outcomes for millions. #DiabetesAwarenessMonth #LiverHealth #NAFLD #NASH #LiverCare #Diabetes #LIVERFASt #LIVERSTAT

Happy Deepavali from Fibronostics! As we celebrate the Festival of Lights, we are reminded of the power of light to dispel darkness and hope to overcome challenges. May this Deepavali bring joy, health, and prosperity to you and your loved ones. At Fibronostics, we are grateful for the trust and support of our clients, partners, and community. Let’s continue working together to bring light to healthcare through innovation and dedication. Wishing everyone a bright, safe, and prosperous Deepavali! #Deepavali #FestivalOfLights #Fibronostics #HealthcareInnovation

Understanding MASH & MASLD The global rise of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)—formerly known as NAFLD—is alarming, with a subset of patients progressing to Metabolic dysfunction-Associated Steatohepatitis (MASH), a more severe stage of liver damage. Early detection and proactive management are crucial in reversing or slowing the progression of MASLD/MASH. At Fibronostics, we provide innovative, non-invasive diagnostic tools like LIVERFASt? that help clinicians detect and monitor liver health with precision. By offering an accessible alternative to liver biopsy, LIVERFASt? delivers critical insights into liver fibrosis, steatosis, and inflammation—empowering healthcare professionals to take timely action for their patients. Let’s work together to turn the tide on liver disease! #MASLD #MASH #LiverHealth #Fibronostics #LIVERFASt #LIVERSTAT #HealthcareInnovation #LiverCare